Compare Realty Income Corp (O) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Realty Income Corp vs Regeneron Pharmaceuticals Inc — how do they compare? Realty Income Corp trades at $65.09 (market cap $60.60B), while Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Realty Income Corp pays the higher dividend (5%). Which is the better fit depends on your goals.
| O | REGN | |
|---|---|---|
Market Cap | $60.60B | $70.79B |
Sector | Real Estate | Health |
52-Week High | $67.56 | $812.27 |
52-Week Low | $55.93 | $545.46 |
Enterprise Value | $90.40B | $64.74B |
Dividend Yield | 5% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Realty Income (O) trades at $64.99, down 1.1% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported revenue of $5.75B in 2025 with a net income margin of 19.05%, though recent quarterly EPS results have missed expectations. Analyst consensus is a Hold with a $67.43 price target, and the stock offers a consistent dividend, recently paying $0.27 per share.
Outlook remains mixed; growth via partnerships and a high 5.14% yield are positives, but elevated P/E of 53.43 and consecutive EPS misses pose risks. Investors should weigh the reliable income stream against valuation concerns and interest rate sensitivity.
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
